Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Paul Wheatley-Price Clear advanced filters

  • In the phase 2 HUDSON study, patients with advanced non-small-cell lung cancer received anti-PD-L1 combined with biomarker-guided therapy targeting ATR kinase, PARP, STAT3 or CD73, leading to encouraging clinical benefit in response to combination of the ATR kinase inhibitor ceralasertib with durvalumab.

    • Benjamin Besse
    • Elvire Pons-Tostivint
    • John V. Heymach
    ResearchOpen Access
    Nature Medicine
    Volume: 30, P: 716-729

  • In the first stage of the BR.36 adaptive trial in patients with non-small cell lung cancer receiving anti-PD1 immunnotherapy, the primary endpoint of concordance between circulating tumor DNA (ctDNA) molecular response and RECIST response was met. The results will inform the second, ctDNA-directed stage.

    • Valsamo Anagnostou
    • Cheryl Ho
    • Janet Dancey
    ResearchOpen Access
    Nature Medicine
    Volume: 29, P: 2559-2569